AstraZeneca Helps More People Afford Its Medicines
02 Novembre 2006 - 12:00PM
PR Newswire (US)
Increased Income Level May Qualify Millions More People For Free
Program WILMINGTON, Del., Nov. 2 /PRNewswire-FirstCall/ --
AstraZeneca today announced new efforts to help people who have
difficulty paying for their medicines. Beginning November 15th, a
family of four earning $60,000 or less or individuals earnings
$30,000 or less, who do not have prescription drug coverage, can
qualify to get their AstraZeneca medicines for free. This change to
the AstraZeneca Patient Assistance Program means that an additional
3.8 million people may be helped, bringing the total uninsured
population that may qualify to approximately 33 million people. It
directly helps those in the middle class as well as those with
lower incomes. "People struggle every day to pay for their health
care. Part of AstraZeneca's core commitment to patients is to
enable those who can't afford our medicines to get them, regardless
of their ability to pay," said Tony Zook, President and CEO,
AstraZeneca US. "Expanding this program means that a family earning
the median US household income of around $46,000 will be able to
qualify for our program-we think that's a significant step in the
right direction." Congressman Jim Clyburn, Chair of the Democratic
Caucus, said, "Today AstraZeneca showed what a truly caring company
does when it knows people need assistance. By standing with average
working families who can't afford their medicines, AstraZeneca has
made a lasting impact by making sure their medicines are
accessible." Expanding the number of people who will be able to
obtain AstraZeneca's medicines for free, is part of AstraZeneca's
overall effort to ensure that people who are having difficulty
accessing and affording their treatments have the company's
support. In addition to providing medicines free of charge, the
AstraZeneca Patient Assistance Program provides one-on-one
education and information to help individuals obtain whichever
medicines their doctor recommends, even if they are made by another
manufacturer. "One of our chief concerns at AARP is making sure all
Americans have access to affordable prescription drugs. When
companies like AstraZeneca find ways to help more Americans get the
prescription drugs they need, it's a positive step in the right
direction," said John Rother, Group Executive Officer, Policy and
Strategy, AARP. The AstraZeneca Patient Assistance Program provides
assistance for qualifying families of four earning $60,000 or less
per year or qualifying individuals earnings $30,000 or less per
year-which is based on approximately 300 percent of the Federal
Poverty Level (FPL). The program provides assistance to people of
all ages without drug coverage. People with drug coverage
experiencing financial hardship, including people with Medicare
Part D, may also apply to the program for interim assistance. "This
is one of the most comprehensive industry responses to the issue of
prescription drug assistance for those people who can't afford
their medicines," said Jane L. Delgado, Ph.D. M.S., President and
CEO of the National Alliance for Hispanic Health, the nation's
leading Hispanic health advocacy group. "It's our hope that others
in the industry will follow AstraZeneca's move to expand patient
assistance programs and make their medicines more available for
those who need them most." AstraZeneca was the first pharmaceutical
company to include information about its assistance program in all
of its television advertisements. Later in November, AstraZeneca
will also launch a national print and web advertising campaign to
raise awareness among consumers who may be eligible for the
AstraZeneca Patient Assistance Program. For nearly three decades,
AstraZeneca has offered drug assistance programs side by side with
its medicines. In 2005, through the AstraZeneca drug assistance
programs, AstraZeneca provided more than $751 million in savings to
more than 712,000 patients without drug coverage throughout the US
and Puerto Rico. People who need information about the PAP can call
800-424-3727 or visit http://www.astrazeneca-us.com/drugassistance.
Starting November 16th, patients can also call 1-800-azandme, or
visit, http://www.azandme.com/. AstraZeneca is a major
international healthcare business engaged in the research,
development, manufacture and marketing of prescription
pharmaceuticals and the supply of healthcare services. It is one of
the world's leading pharmaceutical companies with healthcare sales
of $23.95 billion and leading positions in sales of
gastrointestinal, cardiovascular, neuroscience, respiratory,
oncology and infection products. In the United States, AstraZeneca
is a $10.77 billion healthcare business with more than 12,000
employees. AstraZeneca is listed in the Dow Jones Sustainability
Index (Global) as well as the FTSE4Good Index. For more information
about AstraZeneca, please visit: http://www.astrazeneca-us.com/.
DATASOURCE: AstraZeneca CONTACT: Emily Denney, +1-302-885-3451, ,
or Abby Baron, +1-302-885-3578, , both of AstraZeneca LP Web site:
http://www.astrazeneca-us.com/ Company News On-Call:
http://www.prnewswire.com/comp/985887.html
Copyright